13-THY-03-AZ (D4203C00011) [VERIFY]Phase III Study of Vandetanib in Advanced Radioiodine Refractory Thyroid Cancers

Grants and Contracts Details

StatusFinished
Effective start/end date1/8/14 → 6/30/17

Funding

  • AstraZeneca Pharmaceuticals AB: $399,586.00